BRAINWeek 2024 will close the brain health knowledge gap for health care providers (HCPs) who treat patients every day in their communities.

As an HCP, you’ll benefit from actionable, current information such as the latest research, treatment information, best practices, and other insights into neurological illness and mental illness. You’ll increase your knowledge about how to better assess, diagnose, and appropriately refer patients with brain health concerns. BRAINWeek’s expert faculty will delve into clinical and behavioral discussions surrounding some of the most frequent and pressing challenges HCPs face in their practices today. Courses may include integrative approaches to knowledge, for example, the relationship between nutrition and depression; exercise on the progression of Alzheimer’s; and use of the emerging treatment psilocybin (mushrooms) for mental health conditions, to name a few. You’ll also hear nationally known keynotes speakers, attend networking events, and have time to connect with colleagues. 

KEYNOTE SPEAKERS

Kristin Lee, Ed.D., LICSW

Kristen Lee, Ed.D., LICSW

Dr. Kristen Lee, Ed.D., LICSW, known as “Dr. Kris”, is an internationally recognized, award-winning behavioral science clinician, researcher, educator, speaker, comedian, and from Boston, Massachusetts. As the Lead Faculty for Behavioral Science and Faculty-in-Residence at Northeastern University, Dr. Kris’s research and teaching interests include individual and organizational well-being and resilience, particularly for marginalized and underserved populations.

Dr. Kris works with organizations and leaders around the world on how to use the science of behavioral change and human potential to build healthy mental health cultures that help prevent burnout and promote organizational and human sustainability.

Wade Cooper

Wade Cooper, DO

Dr. Cooper earned his medical degree from Michigan State University College of Osteopathic Medicine. He completed a neurology residency at Michigan State University and is board-certified in Neurology and Psychiatry. Dr. Cooper obtained a fellowship in Headache Medicine from the Michigan Head Pain and Neurological Institute in Ann Arbor.

Prior to joining Memorial Healthcare Institute for Neuroscience, Dr. Cooper was a Director at the Headache & Neuropathic Pain Clinic and Program Director of the Headache Medicine Fellowship Training Program at the University of Michigan, Ann Arbor. He is a Fellow for the American Headache Society and serves on several neurological boards and committees.

FACULTY

Dive into faculty bios by clicking each name below. 

Director, UCLA Sleep Disorders Center
Los Angeles, California
President/Psychiatrist
Las Vegas, Nevada
Psychological Therapist
Phoenix, Arizona
Neurologist/Psychiatrist
Scottsdale, Arizona
Clinical Assistant Professor & Clinical Pain/Addiction Pharmacist
Morgantown, West Virginia
Director of Integrative Pain Management
Miami, Florida
Nurse Author
Brandon, Florida
Assistant Professor of Neurology
Sharon, Massachusetts
Physical Medicine & Rehabilitation
Scottsdale, Arizona
Adult Nurse Practitioner
San Carlos, California

AGENDA

Click into each session below for more information.

  • Thursday, May 9

  • End Time: 7:30a

    End Time: 8:20a

    Location: Kierland Ballroom

    Faculty: Mark Garofoli, PharmD, MBA, BCGP, CPE

    Press Number: BRW-01

    Course Description:

    “Medical” Marijuana, Recreational Marijuana, Weed, Hemp, Cannabis, Cannabinoids, CBD, THC, when will the madness end, or begin? Cannabis has been around for centuries, and debates continue as to its usefulness and legality. Almost every U.S. state has had a legal shift in regards to Cannabis in some form or fashion. Bring any “budding” questions as we provide a “higher education” of clinically practical knowledge, with a dash of entertainment, for all things Cannabis. It’s time to dive deeper into the weeds.

    Attendees will be able to understand and explain the pharmacological properties of Cannabis and Cannabinoids that contribute to polarized, sensationalized, and generally misunderstood conversations across our country.

    A comprehensive, yet succinct, discussion of the Cannabis and Cannabinoids including dynamic patient care principles.

    Learning Objectives:

    • Recall cannabis and cannabinoid history, products, and, legality efforts
    • Identify cannabis and cannabinoid patient counseling opportunities
    • Discuss cannabis and cannabinoid effects including dosage, interactions, and side effects
    • Recall cannabis and cannabinoid utilization opportunities for various medical conditions

    End Time: 9:15a

    Press Number: PDM-01

    End Time: 9:35a

    End Time: 10:25a

    Location: Kierland Ballroom

    Pres Number: BRW-02

    Faculty: Theresa (Tracey) Mallick-Searle, MS, PMGT-BC, ANP-BC

    Course Description: 

    The endocannabinoid system has a regulatory role in both the central nervous system (CNS) and peripheral processes. It also has been shown to have immunoregulatory properties. A basic understanding of the functioning and regulation of endocannabinoid system, will provide the clinician in neurosciences and mental/behavioral health with a greater appreciation for the role of this homeostatic regulatory system on anxiety, depression, neurogenesis, neurological health, reward, cognition, learning, and memory.

    Currently, there are NO states in the U.S. that DO NOT have legalization for either medicinal or recreational cannabis use, including the federal legality of CBD from hemp with less than 0.3% THC.

    This session will provide basic, non-biased, concise and useful information to Clinicians that is vital to guide the safe treatment and counseling of their patients. In addition, an understanding and appreciation for the role of the endocannabinoid system, in maintaining neurological stability and the role it plays in chronic neurological disease will allow the audience to destigmatize the medicinal use of cannabis in their patients.

    Learning Objectives:

    • Define the endocannabinoid system (eCS)
    • Discuss the effects of cannabis on the eCS
    • Describe the involvement of the eCS in wellness and disease

    End Time: 11:20a

    Location: Kierland Ballroom

    Pres Number: BRW-03

    Faculty: Ann Childress, MD

    Learning Objectives:
    • Recognize characteristics/types of attention deficit hyperactivity disorder (ADHD) in pediatric and adult populations
    • Evaluate characteristics of ADHD in both children and adults
    • Describe disparities in the diagnosis and treatment of ADHD
    • Describe the long-term implications of ADHD on overall health, quality of life, and cognitive development

    End Time: 12:00p

    End Time: 1:00p

    End Time: 2:00

    Location: Kierland Ballroom

    Pres Number: BRW-04

    Faculty: Alon Y. Avidan, MD, MPH, HAAN, FAASM

    Course Description:

    Let’s take a walk-through dreamland! In this course, our expert faculty speaker will lead us on an explorative journey through the implications of insomnia, and comorbid primary sleep, medical and psychiatric disorders on overall health. Learners will be given tools to help uncover treatment and management strategies to help optimize patient care. Sleep deficiency is linked to multiple chronic health issues, including heart disease, kidney disease, high blood pressure, diabetes, stroke, obesity, and depression. It is also associated with a higher risk of accidents and injury, including serious car crashes, plane crashes, broken bones, and falls. This BRAINWeek session will provide both frontline clinicians and specialists with expert and comprehensive insights into how to accurately recognize signs of chronic insomnia disorder in clinical practice and will help learners apply appropriate care strategies to enhance patient outcomes and overall well-being. This session will also discuss the complexities of comorbid psychiatric conditions, their bidirectionality with sleep disturbances and their adverse impact on health.

    Learning Objectives:

    • Discuss the mechanisms of insomnia, the most prevalent sleep disorder in the United States
    • Identify characteristics of insomnia and unique subtypes
    • Recognize characteristics of insomnia and comorbidities in clinical practice settings
    • Describe the impact of insomnia on health-related quality of life and daily functioning
    • Discuss the implications of psychiatric comorbidities such as depression and pain on sleep health
    • Identify behavioral and pharmacologic management strategies to optimize patient care outcomes in individuals with insomnia

    End Time: 2:55

    Location: Kierland Ballroom

    Press Number: BRW-05

    Faculty: Ann Childress, MD

    Learning Objectives:

    • Describe current pharmacological (stimulants/non-stimulants/combination therapy) and non-pharmacological (psychosocial interventions, lifestyle modifications) treatment approaches in ADHD
    • Describe the efficacy, benefits, and adverse effects of pharmacological and non-pharmacological treatments
    • Select and individualize appropriate treatment regimens for patients with ADHD
    • Discuss challenges with treatment adherence among patients with ADHD and how to mitigate challenges

    End Time: 3:30p

    End Time: 4:35p

    Location: Kierland Ballroom

    Pres Number: BRW-06

    Faculty: Paul Mathew, MD, DNBPAS, FAAN, FAHS

    Course Description:

    Headache is one of the most common complaints among patients presenting to an outpatient primary care, neurology, or pain practice. The evaluation, diagnosis, and treatment of headache can be rather cumbersome, and at times quite challenging for even the most seasoned clinician. Many complex issues that although not causative, can play a triggering role in the genesis of headaches.

    This presentation will review some of the essential elements that are part of headache evaluation including headache-specific history, physical examination, warning signs of secondary headache disorders, and when to consider additional studies.

    Learning Objectives:

    • Classify headaches based on International Headache Society criteria
    • Formulate an effective treatment plan for headache disorders that considers both pharmacological and non-pharmacological interventions
    • Describe evaluation approaches needed to make an accurate and comprehensive assessment of headache characteristics to determine diagnosis

    End Time: 5:45p

    Press Number: KEY-01

    Faculty: Dr. Cooper

    Course Description:

    The current treatment landscape for migraine has seen an emergence of new and more effective pharmacological and non-pharmacological therapeutic options, particularly for patients with refractory and more challenging migraine presentations. In addition, advancements in research have opened doors to other useful discoveries regarding the link between migraine and the gut-brain axis and autonomic control. This pivotal and dynamic keynote session will help clinicians optimize care in patients with migraine by outlining the effectiveness and applicability of new treatment options, and by examining novel research discoveries that have the propensity to alter the course of migraine treatment and management.

    Learning Objectives:

    • Describe the effectiveness of newer pharmacological and non-pharmacological treatment strategies for migraine, including CGRP-receptor antagonists, CGRP antibodies, 5-HT1F receptor agonists, and new deliveries for treatments in intranasal form as well as non-invasive neuromodulation.
    • Identify which patients are suitable candidates for newer approved therapies for migraine.
    • Discuss the involvement of the gut-brain axis and the autonomic nervous system in migraine pathogenesis and progression.

    End Time: 6:30p

    Location: Exhibit Hall

  • Friday, May 10

  • End Time: 7:30a

    End Time: 8:20a

    Location: Kierland Ballroom

    Pres Number: BRW-07

    Faculty: Shana Johnson, MD

    Course Description:

    Central sensitization syndromes (CSS) affect upwards of 30 million adults in the United States and the role of sensitization in migraine is not yet widely understood outside of chronic pain and neurology clinics.

    The presentation will focus on the diagnosis and management of migraines with sensitization and provide real-world examples and evidence-based research to enhance the providers’ clinical knowledge and skills to be able to identify when sensitization is present and allow them to tailor the treatment plan accordingly. Educating patients on sensitization reduces overutilization of healthcare resources as patients understand how sensitization affects their symptoms and are less prone to catastrophic thinking that a new or worsening illness is occurring with symptoms flares they are better able to self-manage.

    Learning Objectives:

    • Describe the pathophysiologic process of central sensitization
    • Discuss how sensitization affects approaches to migraine treatment and management
    • Explain the interplay of migraine treatment with mental health disorders, stress, and sleep

    End Time: 9:15a

    Pres Number: PDM-04

    End Time: 9:35a

    End Time: 10:25a

    Location: Kierland Ballroom

    Press Number: BRW-08

    Faculty: Dani Cabral, MD

    Learning Objectives:

    • Describe appropriate assessment tools for screening and evaluating patients for neurocognitive disorders (NCDs), including mild cognitive impairment and dementia.
    • Recognize characteristics of NCDs in clinical practice.
    • Describe diagnostic criteria for NCD syndromes.
     

    End Time: 11:20a

    Location: Kierland Ballroom

    Press Number: BRW-09

    Faculty: Theresa (Tracey) Mallick-Searle, MS, PMGT-BC, ANP-BC

    Course Description:

    The gut and brain connect via a neuro-immuno-humoral network of signaling pathways known as the gut–brain axis, which includes the vagus nerve, the immune system, the hormonal system. Disturbances of microbiota homeostasis and dysregulation of these pathways can cause pathological malfunctions, including neurological disorders.

    Increasing preclinical and clinical studies/evidence indicate that gut microbes are a possible susceptibility factor for the progression of neurological disorders, including Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS) and autism spectrum disorder (ASD).

    This session will examine what is known in the literature and where the research is heading in the examination of the connection between the gut microbiota and the central nervous system. Practical recommendations that clinicians can make to their patients to aid in the prevention and treatment of gut microbiota-related neurological disorders will be addressed.

    Learning Objectives:

    • Define the gut-brain axis
    • Explain the role of the microbiome in central nervous system functioning and the pathogenesis of neurological disorders
    • Identify key neurological conditions that have been studied in relationship to the microbiome
    • Recall nutritional interventions that support the health of the microbiome

    End Time: 12:15p

    Room: Kierland Ballroom

    Pres Number: BRW-10

    Faculty: Alon Y. Avidan, MD, MPH, HAAN, FAASM

    Course Description:
    In this stimulating and expert-led session, we’re bringing the frontlines of sleep management and treatment to you! Although nearly 50 to 70 million Americans suffer from chronic, or ongoing, sleep disorders. Severe sleepiness is common in clinical psychiatric and neurological care, but it is often overlooked in practice, which when left unchecked, can have dire consequences for patient health and worsen depression. Join our expert faculty speaker for a vigorous examination of central disorders of hypersomnolence including narcolepsy. The discussion will provide an overview of symptom recognition and an opportunity to survey current data to improve early diagnosis of these disorders in clinical practice, understand the bidirectional relationship between these conditions and psychiatric health, and appraise current management guidelines and strategies to improve the care of people with narcolepsy and hypersomnolence.

    Learning Objectives:

    • Identify the clinical characteristics of narcolepsy types 1 and 2 and idiopathic hypersomnia (IH)
    • Discuss the differential diagnosis of hypersomnia and narcolepsy
    • Describe the differences between narcolepsy type 1, narcolepsy type 2, and IH
    • Describe the implications of central disorders of hypersomnia on the patient’s overall health and activities of daily living
    • Discuss the association between hypersomnia and psychiatric disorders, including mood disorders
    • Describe treatments and management strategies for patients with hypersomnia and narcolepsy, including patients with comorbid conditions
     

    End Time: 12:30p

    End Time: 1:30p

    Pres Number: PDM-05

    Topic: Migraine

    Company: Lilly

    End Time: 2:30p

    Location: Kierland Ballroom

    Press Number: BRW-11

    Faculty: Dani Cabral, MD

    Course Description:

    In 2023, there were 6.5 million Americans with dementia, most of whom have Alzheimer’s disease as the cause. This presentation will highlight recent scientific advances in Alzheimer’s disease diagnosis/treatment and translate them into real-world clinical practice highlighting what we know and the remaining gaps. The progress on Alzheimer’s is exciting but remains controversial infused with important questions about the clinical meaningfulness of the treatments given potential serious side effects and high financial costs along with practical challenges for patients, families, healthcare providers, and payors.

    The course will enhance critical thinking skills, clinical knowledge and skills by:
    1.) Enhancing understanding of the role of biomarkers in Alzheimer’s diagnosis providing practical guidance on current clinical use and reimbursement
    2.) Explaining clinical trial data for FDA-approved Alzheimer’s treatment including lack of diversity in study subjects, applicability to clinical practice, and discussion of systems needed for safe prescribing and monitoring.

    Learning Objectives:

    • Describe the role of biomarkers in Alzheimer’s diagnosis
    • Discuss recent FDA-approved treatments for Alzheimer’s disease, including mechanisms of action, applicability to clinical practice, systems needed for safe prescribing  and monitoring, the generalizability of treatments to diverse populations, and costs
    • Discuss real-world practices for safe prescribing and monitoring of anti-amyloid monoclonal antibody treatments for Alzheimer’s disease while considering potential collaborations between primary care providers and specialists
    • Recognize patients who should be considered for Alzheimer’s evaluation, diagnosis, or treatment
    • Identify gaps in comprehensive dementia care needs of patients and families
    • Employ clinical practices to optimize the care of older patients with or at risk for Alzheimer’s disease

    End Time: 3:25p

    Location: Kierland Ballroom

    Pres Number: BRW-12

    Faculty: Da’mond Gadson, DBH, LPC, MPC, MED

    Course Description:

    Research regarding the interaction between physical and mental health integration has recently gained momentum due to the increasing demand for healthcare providers to identify and provide impactful care during patient interactions. Unfortunately, the growing levels of daily trauma have made a significant impact on the effectiveness of treating patients with physical health needs.

    This session will discuss how trauma and mental health mobilize in physical health environments and how a mental health provider may support your practice’s integrated care needs. Content will also include reviewing assessment tools to use when trauma or a mental health need is suspected and how to work collaboratively with mental health professionals off-site for patient retention.

    Learning Obectives:

    • Select standard assessment tools to evaluate depression and anxiety in clinical settings
    • Describe the characteristics of patients with trauma
    • Identify opportunities for providing integrated mental and physical health care services
    • Discuss the benefits of integrated mental health care

    End Time: 3:55p

    End Time: 4:45p

    Location: Kierland Ballroom

    Press Number: BRW-13

    Faculty: Paul Mathew, MD, DNBPAS, FAAN, FAHS

    Course Description:

    Clinician Burnout is highly prevalent, affecting over 50% of clinicians in some studies. With such a phenomenon affecting so many clinicians, there can be systemwide impacts. Burnout can result in clinicians reducing their hours, changing jobs, or even leaving healthcare to seek employment in other fields, which reduces access and continuity of care. Burnout can also result in reductions in care quality and patient safety.

    In this lecture, strategies for both the individual and institution to address clinician burnout will be discussed. With practical and implementable strategies, clinician burnout can be mitigated and potentially prevented.

    Learning Objectives:

    • Identify the causes and symptoms of physician burn out
    • Formulate an effective treatment plan to help individuals and health systems reduce clinician burn out

    End Time: 5:55p

    Press Number: KEY-02

    Faculty: Kristen Lee, Ed.D., LICSW

    Course Description:

    Within today’s “Age of Anxiety” and global mental health crisis, we need tangible ways to protect against burnout and optimize outcomes. This keynote teaches evidence-based habits, mindsets, and practices to help cope with and endeavor change. The science of human flourishing and behavioral change offers a host of proven ways we can progress towards better individual and collective outcomes. This keynote provides a “double dip” toolbox of interactive, practical, evidence-based strategies to cultivate resilience and optimize well-being within the care continuum.

    Credit: not certified for credit

    End Time: 7:00p

    Location: Exhibit Hallway

  • Saturday, May 11

  • End Time: 8:20a

    Location: Kierland Ballroom

    Pres Number: BRW-14

    Faculty: Mark P. Garofoli, PharmD, MBA, BCGP, CPE, CTTS

    Course Description:

    Where to begin an understanding? The pharmacology, history, and policy of course. This session will dynamically review the foundational pharmacology of hallucinogens and discuss a brief history and policy respectively. All culminating with clinical pearls to directly improve patient care for attendees immediately.

    Learning Objectives:

    • Recall the classifications of hallucinogens
    • Produce safety information to prevent overdose and mitigate side effects in patients using psychedelics to treat medical conditions
    • Describe the historical and current legal control status of psychedelics relative to respective mechanism(s) of action

    End Time: 9:15a

    Pres Number: PDM-07

    End Time: 9:35a

    End Time: 10:25a

    Location: Kierland Ballroom

    Press Number: BRW-15

    Faculty: Natalie Goldberg, LPN

    Course Description:
    This session will examine the use of psychedelics, with a focus on psilocybin, in the treatment of psychological trauma and post-traumatic stress disorders (PTSD). Providing perspective through a unique lens, an account of a nurse’s personal health journey involving treatment with psychedelics will be explored, merging both personal and clinical knowledge and experiences. This multimodal presentation will synthesize current research findings and personal insights to provide clinicians with knowledge regarding the efficacy of psychedelics in trauma therapy, including benefits and risks, and the role of shared decision-making and multidisciplinary care in optimizing patient outcomes.

    Learning Objectives:

    • Describe a patient’s experience with complementary and/or alternative treatment modalities for conditions such as anxiety, sleep disorders, and chronic pain

    End Time: 11:20a

    Location: Kierland Ballroom

    Press Number: BRW-16

    Faculty: Mark P. Garofoli, PharmD, MBA, BCGP, CPE, CTTS

    Course Description:

    Given the chaotic overlapping landscape of illicit substances, prescription medications, over-the-counter medications, and supplements, it’s easy for clinicians to get lost in the “delirium” when it comes to knowing which substances, including formulations and dosages, are FDA-approved for patient care, under clinical study, not approved for patient use, or outright illegal on a federal or state level.

    Alas, this session will aim to review FDA-approved psychedelic medications, research studies, and case studies in an effort to clear the “haze” on what psychedelic medications clinicians can actually consider when providing patient care. Let’s take a trip, to optimized patient care!

    Learning Objectives:

    • Recall the FDA-approved medications that are also hallucinogens at other dosages and formulations.
    • Identify the appropriate condition-specific dosages of FDA-approved medications that are also hallucinogens at other dosages and formulations.
    • Recall the side effects and drug-drug interactions of FDA-approved medications that are also hallucinogens at other dosages and formulations.

    End Time: 11:30a

    End Time: 12:30p

    Pres Number: BRW-17

    Faculty: Michelle Weiner, DO, MPH

    Course Description:

    This extraordinary session will provide a comprehensive and dynamic perspective on the use of psychedelic therapies in the treatment of brain and mental health conditions, including the value and benefits of employing these new and emerging treatment modalities in practice, potential risks, and the plausibility of these non-traditional therapeutic approaches being implemented into the existing treatment armamentarium for brain and mental health conditions. Grounded in evidence-based research findings, this session will provide a holistic and balanced clinical perspective on both the current state of evidence regarding what the medical community has discovered about the implications of the use of psychedelics in clinical practice, and about the future use of psychedelics as a therapeutic option for addressing brain and mental health disorders.

End Time: 7:30a

End Time: 8:20a

Location: Kierland Ballroom

Faculty: Mark Garofoli, PharmD, MBA, BCGP, CPE

Press Number: BRW-01

Course Description:

“Medical” Marijuana, Recreational Marijuana, Weed, Hemp, Cannabis, Cannabinoids, CBD, THC, when will the madness end, or begin? Cannabis has been around for centuries, and debates continue as to its usefulness and legality. Almost every U.S. state has had a legal shift in regards to Cannabis in some form or fashion. Bring any “budding” questions as we provide a “higher education” of clinically practical knowledge, with a dash of entertainment, for all things Cannabis. It’s time to dive deeper into the weeds.

Attendees will be able to understand and explain the pharmacological properties of Cannabis and Cannabinoids that contribute to polarized, sensationalized, and generally misunderstood conversations across our country.

A comprehensive, yet succinct, discussion of the Cannabis and Cannabinoids including dynamic patient care principles.

Learning Objectives:

  • Recall cannabis and cannabinoid history, products, and, legality efforts
  • Identify cannabis and cannabinoid patient counseling opportunities
  • Discuss cannabis and cannabinoid effects including dosage, interactions, and side effects
  • Recall cannabis and cannabinoid utilization opportunities for various medical conditions

End Time: 9:15a

Press Number: PDM-01

End Time: 9:35a

End Time: 10:25a

Location: Kierland Ballroom

Pres Number: BRW-02

Faculty: Theresa (Tracey) Mallick-Searle, MS, PMGT-BC, ANP-BC

Course Description: 

The endocannabinoid system has a regulatory role in both the central nervous system (CNS) and peripheral processes. It also has been shown to have immunoregulatory properties. A basic understanding of the functioning and regulation of endocannabinoid system, will provide the clinician in neurosciences and mental/behavioral health with a greater appreciation for the role of this homeostatic regulatory system on anxiety, depression, neurogenesis, neurological health, reward, cognition, learning, and memory.

Currently, there are NO states in the U.S. that DO NOT have legalization for either medicinal or recreational cannabis use, including the federal legality of CBD from hemp with less than 0.3% THC.

This session will provide basic, non-biased, concise and useful information to Clinicians that is vital to guide the safe treatment and counseling of their patients. In addition, an understanding and appreciation for the role of the endocannabinoid system, in maintaining neurological stability and the role it plays in chronic neurological disease will allow the audience to destigmatize the medicinal use of cannabis in their patients.

Learning Objectives:

  • Define the endocannabinoid system (eCS)
  • Discuss the effects of cannabis on the eCS
  • Describe the involvement of the eCS in wellness and disease

End Time: 11:20a

Location: Kierland Ballroom

Pres Number: BRW-03

Faculty: Ann Childress, MD

Learning Objectives:
  • Recognize characteristics/types of attention deficit hyperactivity disorder (ADHD) in pediatric and adult populations
  • Evaluate characteristics of ADHD in both children and adults
  • Describe disparities in the diagnosis and treatment of ADHD
  • Describe the long-term implications of ADHD on overall health, quality of life, and cognitive development

End Time: 12:00p

End Time: 1:00p

End Time: 2:00

Location: Kierland Ballroom

Pres Number: BRW-04

Faculty: Alon Y. Avidan, MD, MPH, HAAN, FAASM

Course Description:

Let’s take a walk-through dreamland! In this course, our expert faculty speaker will lead us on an explorative journey through the implications of insomnia, and comorbid primary sleep, medical and psychiatric disorders on overall health. Learners will be given tools to help uncover treatment and management strategies to help optimize patient care. Sleep deficiency is linked to multiple chronic health issues, including heart disease, kidney disease, high blood pressure, diabetes, stroke, obesity, and depression. It is also associated with a higher risk of accidents and injury, including serious car crashes, plane crashes, broken bones, and falls. This BRAINWeek session will provide both frontline clinicians and specialists with expert and comprehensive insights into how to accurately recognize signs of chronic insomnia disorder in clinical practice and will help learners apply appropriate care strategies to enhance patient outcomes and overall well-being. This session will also discuss the complexities of comorbid psychiatric conditions, their bidirectionality with sleep disturbances and their adverse impact on health.

Learning Objectives:

  • Discuss the mechanisms of insomnia, the most prevalent sleep disorder in the United States
  • Identify characteristics of insomnia and unique subtypes
  • Recognize characteristics of insomnia and comorbidities in clinical practice settings
  • Describe the impact of insomnia on health-related quality of life and daily functioning
  • Discuss the implications of psychiatric comorbidities such as depression and pain on sleep health
  • Identify behavioral and pharmacologic management strategies to optimize patient care outcomes in individuals with insomnia

End Time: 2:55

Location: Kierland Ballroom

Press Number: BRW-05

Faculty: Ann Childress, MD

Learning Objectives:

  • Describe current pharmacological (stimulants/non-stimulants/combination therapy) and non-pharmacological (psychosocial interventions, lifestyle modifications) treatment approaches in ADHD
  • Describe the efficacy, benefits, and adverse effects of pharmacological and non-pharmacological treatments
  • Select and individualize appropriate treatment regimens for patients with ADHD
  • Discuss challenges with treatment adherence among patients with ADHD and how to mitigate challenges

End Time: 3:30p

End Time: 4:35p

Location: Kierland Ballroom

Pres Number: BRW-06

Faculty: Paul Mathew, MD, DNBPAS, FAAN, FAHS

Course Description:

Headache is one of the most common complaints among patients presenting to an outpatient primary care, neurology, or pain practice. The evaluation, diagnosis, and treatment of headache can be rather cumbersome, and at times quite challenging for even the most seasoned clinician. Many complex issues that although not causative, can play a triggering role in the genesis of headaches.

This presentation will review some of the essential elements that are part of headache evaluation including headache-specific history, physical examination, warning signs of secondary headache disorders, and when to consider additional studies.

Learning Objectives:

  • Classify headaches based on International Headache Society criteria
  • Formulate an effective treatment plan for headache disorders that considers both pharmacological and non-pharmacological interventions
  • Describe evaluation approaches needed to make an accurate and comprehensive assessment of headache characteristics to determine diagnosis

End Time: 5:45p

Press Number: KEY-01

Faculty: Dr. Cooper

Course Description:

The current treatment landscape for migraine has seen an emergence of new and more effective pharmacological and non-pharmacological therapeutic options, particularly for patients with refractory and more challenging migraine presentations. In addition, advancements in research have opened doors to other useful discoveries regarding the link between migraine and the gut-brain axis and autonomic control. This pivotal and dynamic keynote session will help clinicians optimize care in patients with migraine by outlining the effectiveness and applicability of new treatment options, and by examining novel research discoveries that have the propensity to alter the course of migraine treatment and management.

Learning Objectives:

  • Describe the effectiveness of newer pharmacological and non-pharmacological treatment strategies for migraine, including CGRP-receptor antagonists, CGRP antibodies, 5-HT1F receptor agonists, and new deliveries for treatments in intranasal form as well as non-invasive neuromodulation.
  • Identify which patients are suitable candidates for newer approved therapies for migraine.
  • Discuss the involvement of the gut-brain axis and the autonomic nervous system in migraine pathogenesis and progression.

End Time: 6:30p

Location: Exhibit Hall

End Time: 7:30a

End Time: 8:20a

Location: Kierland Ballroom

Pres Number: BRW-07

Faculty: Shana Johnson, MD

Course Description:

Central sensitization syndromes (CSS) affect upwards of 30 million adults in the United States and the role of sensitization in migraine is not yet widely understood outside of chronic pain and neurology clinics.

The presentation will focus on the diagnosis and management of migraines with sensitization and provide real-world examples and evidence-based research to enhance the providers’ clinical knowledge and skills to be able to identify when sensitization is present and allow them to tailor the treatment plan accordingly. Educating patients on sensitization reduces overutilization of healthcare resources as patients understand how sensitization affects their symptoms and are less prone to catastrophic thinking that a new or worsening illness is occurring with symptoms flares they are better able to self-manage.

Learning Objectives:

  • Describe the pathophysiologic process of central sensitization
  • Discuss how sensitization affects approaches to migraine treatment and management
  • Explain the interplay of migraine treatment with mental health disorders, stress, and sleep

End Time: 9:15a

Pres Number: PDM-04

End Time: 9:35a

End Time: 10:25a

Location: Kierland Ballroom

Press Number: BRW-08

Faculty: Dani Cabral, MD

Learning Objectives:

  • Describe appropriate assessment tools for screening and evaluating patients for neurocognitive disorders (NCDs), including mild cognitive impairment and dementia.
  • Recognize characteristics of NCDs in clinical practice.
  • Describe diagnostic criteria for NCD syndromes.
 

End Time: 11:20a

Location: Kierland Ballroom

Press Number: BRW-09

Faculty: Theresa (Tracey) Mallick-Searle, MS, PMGT-BC, ANP-BC

Course Description:

The gut and brain connect via a neuro-immuno-humoral network of signaling pathways known as the gut–brain axis, which includes the vagus nerve, the immune system, the hormonal system. Disturbances of microbiota homeostasis and dysregulation of these pathways can cause pathological malfunctions, including neurological disorders.

Increasing preclinical and clinical studies/evidence indicate that gut microbes are a possible susceptibility factor for the progression of neurological disorders, including Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS) and autism spectrum disorder (ASD).

This session will examine what is known in the literature and where the research is heading in the examination of the connection between the gut microbiota and the central nervous system. Practical recommendations that clinicians can make to their patients to aid in the prevention and treatment of gut microbiota-related neurological disorders will be addressed.

Learning Objectives:

  • Define the gut-brain axis
  • Explain the role of the microbiome in central nervous system functioning and the pathogenesis of neurological disorders
  • Identify key neurological conditions that have been studied in relationship to the microbiome
  • Recall nutritional interventions that support the health of the microbiome

End Time: 12:15p

Room: Kierland Ballroom

Pres Number: BRW-10

Faculty: Alon Y. Avidan, MD, MPH, HAAN, FAASM

Course Description:
In this stimulating and expert-led session, we’re bringing the frontlines of sleep management and treatment to you! Although nearly 50 to 70 million Americans suffer from chronic, or ongoing, sleep disorders. Severe sleepiness is common in clinical psychiatric and neurological care, but it is often overlooked in practice, which when left unchecked, can have dire consequences for patient health and worsen depression. Join our expert faculty speaker for a vigorous examination of central disorders of hypersomnolence including narcolepsy. The discussion will provide an overview of symptom recognition and an opportunity to survey current data to improve early diagnosis of these disorders in clinical practice, understand the bidirectional relationship between these conditions and psychiatric health, and appraise current management guidelines and strategies to improve the care of people with narcolepsy and hypersomnolence.

Learning Objectives:

  • Identify the clinical characteristics of narcolepsy types 1 and 2 and idiopathic hypersomnia (IH)
  • Discuss the differential diagnosis of hypersomnia and narcolepsy
  • Describe the differences between narcolepsy type 1, narcolepsy type 2, and IH
  • Describe the implications of central disorders of hypersomnia on the patient’s overall health and activities of daily living
  • Discuss the association between hypersomnia and psychiatric disorders, including mood disorders
  • Describe treatments and management strategies for patients with hypersomnia and narcolepsy, including patients with comorbid conditions
 

End Time: 12:30p

End Time: 1:30p

Pres Number: PDM-05

Topic: Migraine

Company: Lilly

End Time: 2:30p

Location: Kierland Ballroom

Press Number: BRW-11

Faculty: Dani Cabral, MD

Course Description:

In 2023, there were 6.5 million Americans with dementia, most of whom have Alzheimer’s disease as the cause. This presentation will highlight recent scientific advances in Alzheimer’s disease diagnosis/treatment and translate them into real-world clinical practice highlighting what we know and the remaining gaps. The progress on Alzheimer’s is exciting but remains controversial infused with important questions about the clinical meaningfulness of the treatments given potential serious side effects and high financial costs along with practical challenges for patients, families, healthcare providers, and payors.

The course will enhance critical thinking skills, clinical knowledge and skills by:
1.) Enhancing understanding of the role of biomarkers in Alzheimer’s diagnosis providing practical guidance on current clinical use and reimbursement
2.) Explaining clinical trial data for FDA-approved Alzheimer’s treatment including lack of diversity in study subjects, applicability to clinical practice, and discussion of systems needed for safe prescribing and monitoring.

Learning Objectives:

  • Describe the role of biomarkers in Alzheimer’s diagnosis
  • Discuss recent FDA-approved treatments for Alzheimer’s disease, including mechanisms of action, applicability to clinical practice, systems needed for safe prescribing  and monitoring, the generalizability of treatments to diverse populations, and costs
  • Discuss real-world practices for safe prescribing and monitoring of anti-amyloid monoclonal antibody treatments for Alzheimer’s disease while considering potential collaborations between primary care providers and specialists
  • Recognize patients who should be considered for Alzheimer’s evaluation, diagnosis, or treatment
  • Identify gaps in comprehensive dementia care needs of patients and families
  • Employ clinical practices to optimize the care of older patients with or at risk for Alzheimer’s disease

End Time: 3:25p

Location: Kierland Ballroom

Pres Number: BRW-12

Faculty: Da’mond Gadson, DBH, LPC, MPC, MED

Course Description:

Research regarding the interaction between physical and mental health integration has recently gained momentum due to the increasing demand for healthcare providers to identify and provide impactful care during patient interactions. Unfortunately, the growing levels of daily trauma have made a significant impact on the effectiveness of treating patients with physical health needs.

This session will discuss how trauma and mental health mobilize in physical health environments and how a mental health provider may support your practice’s integrated care needs. Content will also include reviewing assessment tools to use when trauma or a mental health need is suspected and how to work collaboratively with mental health professionals off-site for patient retention.

Learning Obectives:

  • Select standard assessment tools to evaluate depression and anxiety in clinical settings
  • Describe the characteristics of patients with trauma
  • Identify opportunities for providing integrated mental and physical health care services
  • Discuss the benefits of integrated mental health care

End Time: 3:55p

End Time: 4:45p

Location: Kierland Ballroom

Press Number: BRW-13

Faculty: Paul Mathew, MD, DNBPAS, FAAN, FAHS

Course Description:

Clinician Burnout is highly prevalent, affecting over 50% of clinicians in some studies. With such a phenomenon affecting so many clinicians, there can be systemwide impacts. Burnout can result in clinicians reducing their hours, changing jobs, or even leaving healthcare to seek employment in other fields, which reduces access and continuity of care. Burnout can also result in reductions in care quality and patient safety.

In this lecture, strategies for both the individual and institution to address clinician burnout will be discussed. With practical and implementable strategies, clinician burnout can be mitigated and potentially prevented.

Learning Objectives:

  • Identify the causes and symptoms of physician burn out
  • Formulate an effective treatment plan to help individuals and health systems reduce clinician burn out

End Time: 5:55p

Press Number: KEY-02

Faculty: Kristen Lee, Ed.D., LICSW

Course Description:

Within today’s “Age of Anxiety” and global mental health crisis, we need tangible ways to protect against burnout and optimize outcomes. This keynote teaches evidence-based habits, mindsets, and practices to help cope with and endeavor change. The science of human flourishing and behavioral change offers a host of proven ways we can progress towards better individual and collective outcomes. This keynote provides a “double dip” toolbox of interactive, practical, evidence-based strategies to cultivate resilience and optimize well-being within the care continuum.

Credit: not certified for credit

End Time: 7:00p

Location: Exhibit Hallway

End Time: 8:20a

Location: Kierland Ballroom

Pres Number: BRW-14

Faculty: Mark P. Garofoli, PharmD, MBA, BCGP, CPE, CTTS

Course Description:

Where to begin an understanding? The pharmacology, history, and policy of course. This session will dynamically review the foundational pharmacology of hallucinogens and discuss a brief history and policy respectively. All culminating with clinical pearls to directly improve patient care for attendees immediately.

Learning Objectives:

  • Recall the classifications of hallucinogens
  • Produce safety information to prevent overdose and mitigate side effects in patients using psychedelics to treat medical conditions
  • Describe the historical and current legal control status of psychedelics relative to respective mechanism(s) of action

End Time: 9:15a

Pres Number: PDM-07

End Time: 9:35a

End Time: 10:25a

Location: Kierland Ballroom

Press Number: BRW-15

Faculty: Natalie Goldberg, LPN

Course Description:
This session will examine the use of psychedelics, with a focus on psilocybin, in the treatment of psychological trauma and post-traumatic stress disorders (PTSD). Providing perspective through a unique lens, an account of a nurse’s personal health journey involving treatment with psychedelics will be explored, merging both personal and clinical knowledge and experiences. This multimodal presentation will synthesize current research findings and personal insights to provide clinicians with knowledge regarding the efficacy of psychedelics in trauma therapy, including benefits and risks, and the role of shared decision-making and multidisciplinary care in optimizing patient outcomes.

Learning Objectives:

  • Describe a patient’s experience with complementary and/or alternative treatment modalities for conditions such as anxiety, sleep disorders, and chronic pain

End Time: 11:20a

Location: Kierland Ballroom

Press Number: BRW-16

Faculty: Mark P. Garofoli, PharmD, MBA, BCGP, CPE, CTTS

Course Description:

Given the chaotic overlapping landscape of illicit substances, prescription medications, over-the-counter medications, and supplements, it’s easy for clinicians to get lost in the “delirium” when it comes to knowing which substances, including formulations and dosages, are FDA-approved for patient care, under clinical study, not approved for patient use, or outright illegal on a federal or state level.

Alas, this session will aim to review FDA-approved psychedelic medications, research studies, and case studies in an effort to clear the “haze” on what psychedelic medications clinicians can actually consider when providing patient care. Let’s take a trip, to optimized patient care!

Learning Objectives:

  • Recall the FDA-approved medications that are also hallucinogens at other dosages and formulations.
  • Identify the appropriate condition-specific dosages of FDA-approved medications that are also hallucinogens at other dosages and formulations.
  • Recall the side effects and drug-drug interactions of FDA-approved medications that are also hallucinogens at other dosages and formulations.

End Time: 11:30a

End Time: 12:30p

Pres Number: BRW-17

Faculty: Michelle Weiner, DO, MPH

Course Description:

This extraordinary session will provide a comprehensive and dynamic perspective on the use of psychedelic therapies in the treatment of brain and mental health conditions, including the value and benefits of employing these new and emerging treatment modalities in practice, potential risks, and the plausibility of these non-traditional therapeutic approaches being implemented into the existing treatment armamentarium for brain and mental health conditions. Grounded in evidence-based research findings, this session will provide a holistic and balanced clinical perspective on both the current state of evidence regarding what the medical community has discovered about the implications of the use of psychedelics in clinical practice, and about the future use of psychedelics as a therapeutic option for addressing brain and mental health disorders.

EXHIBIT | SPONSORSHIP PROSPECTUS

REGISTRATION

General Registration

$ 599
  • * Non Industry

Allied Health

$ 499
  • * Non Industry

Industry

$ 699
  •  

CONFERENCE VENUE

Conference Venue

Westin Kierland Resort & Spa in Scottsdale, Arizona.

6902 E Greenway Pkwy, Scottsdale, AZ 85254

Phone Number: (480) 624-1000

Excitement is building for BRAINWeek coming to Scottsdale, Arizona on May 9-11, 2024! As such, we encourage you to complete your room reservation as early as possible, as the room block will fill up quickly. Please note the following information and proceed as directed.

Hotel Cost:

$309 per night** (plus taxes and resort fees)    

** Rate availability Wed-Thurs-Fri-Sat – rooms limited – book when registering **


Cancellation Policy

Cancellations must be submitted in writing. If you are calling to cancel, for verification we will still require you to send an email to info@brainweek.org with your intent to cancel. You will receive confirmation of your cancellation via email.

We will offer a 100% refund within 72 hours from the time of purchase less $100 credit card processing fee.

After 72 hours, refunds will be less 50%. All refund requests must be made in writing and post marked or tax stamped no later than 90 days before the event.
No refund will be made if the request is made within 90 days of the educational event. Refunds will not be issued to non-show registrants.
Substitutions are always welcome in lieu of cancellation. No transfers to alternate events will be made if the request is submitted within 90 days of the original event.
Persons who register and fail to attend will not receive a refund. BRAINWeek, at its sole discretion, may transfer your registration to an upcoming conference or to a healthcare provider colleague. Cancellation of your conference registration does not automatically cancel your hotel room reservation. Please contact the hotel to cancel your room; penalties may apply.

Accreditation Information

Activity Overview

As a HCP, you’ll benefit from actionable, current information such as the latest research, treatment information, best practices, and other insights into neurological illness and mental illness. You’ll increase your knowledge about how to better assess, diagnose, and appropriately refer patients with brain health concerns. BRAINWeek’s expert faculty will delve into clinical and behavioral discussions surrounding some of the most frequent and pressing challenges HCPs face in their practices today. Courses may include integrative approaches to knowledge, for example, the relationship between nutrition and depression; exercise on the progression of Alzheimer’s; and use of the emerging treatment psilocybin (mushrooms) for mental health conditions, to name a few. You’ll also hear nationally known keynotes speakers, attend networking events, and have time to connect with colleagues.

This activity is designed for an audience of physicians, nurses, nurse practitioners, physician assistants, pharmacists, psychologists, and other healthcare professionals.

Upon completion of the educational activity, participants should be able to:

  • Recognize characteristics of neurocognitive disorders in clinical practice and select appropriate assessment tools for screening and evaluation.
  • Discuss recent FDA approved treatments for Alzheimer’s disease, including mechanisms of action, applicability to clinical practice, safe prescribing and monitoring, the generalizability of treatments to diverse populations, and costs.
  • Recognize common sleep disorders in clinical practice and select appropriate treatments and management strategies to optimize patient outcomes.
  • Select standard assessment tools to evaluate psychiatric disorders in clinical settings.
  • Select appropriate treatment regimens and integrated care strategies for patients experiencing psychiatric conditions including depression, anxiety, attention deficit hyperactivity disorder (ADHD), and trauma.
  • Describe disparities in the diagnosis and treatment of various brain and mental health conditions and the impact on patient outcomes.
  • Evaluate and diagnose headache disorders and formulate comprehensive treatment strategies that consider pharmacological and non-pharmacological approaches.
  • Discuss the mechanisms of action, safety, and effects of various complementary and alternative therapies on brain and mental health conditions, including legal implications concerning their use.

Statements of credit will be awarded based on the participant’s attendance.  A statement of credit will be available upon completion of an online evaluation/claim credit form. If you have questions about this CE activity, please contact AKH Inc at tbrignoni@akhcme.com.

AKH

CE credit provided by AKH Inc., Advancing Knowledge in Healthcare.

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and BRAINWeek. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 17 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 17 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Credit being awarded: 17 ANCC contact hours.

AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 17 contact hours.

AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 17 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and BRAINWeek.  AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. This activity is approved for 17 contact hour(s) (which includes 0 hour(s) of pharmacology).

Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.

Full notification of commercial support will be provided in the final course syllabus.

Share this event with your community:

Facebook
Twitter
LinkedIn